Bedaquiline plus delamanid for XDR tuberculosis

The combination was initiated in a patient in whom an effective treatment cannot be designed, in the consideration that its potential life-saving benefits outweigh its unknown adverse event risks; in a department in which more than 100 tuberculosis cases a year are admitted to hospital, of which 14...

Celý popis

Podrobná bibliografie

Vydáno v:	The Lancet infectious diseases Ročník 16; číslo 3; s. 294
Hlavní autoři:	Lachâtre, Marie, Rioux, Christophe, Dû, Damien Le, Fréchet-Jachym, Mathilde, Veziris, Nicolas, Bouvet, Elisabeth, Yazdanpanah, Yazdan
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Elsevier Ltd 01.03.2016 Elsevier Limited
Témata:	Antitubercular Agents - therapeutic use Diarylquinolines - therapeutic use Extensively Drug-Resistant Tuberculosis - drug therapy Extensively Drug-Resistant Tuberculosis - surgery Health Services Accessibility Humans Infectious Disease Infectious diseases Male Mycobacterium Nitroimidazoles - therapeutic use Oxazoles - therapeutic use Tuberculosis
ISSN:	1473-3099, 1474-4457, 1474-4457
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!